Global Phenylketonuria Drug

Phenylketonuria Drug Comprehensive Study by Type (Medications, Supplements , Others), Application (Household, Hospital, Others), Symtomps (Classic, Mild, Benign), Test (Diagnostic Test, Screening Test) Players and Region - Global Market Outlook to 2026

Phenylketonuria Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Phenylketonuria Drug Market Scope
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.

The Phenylketonuria Drug market study is segmented by Type (Medications, Supplements  and Others), by Application (Household, Hospital and Others) and major geographies with country level break-up.

The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Phenylketonuria Drug market throughout the predicted period.

BioMarin Pharmaceutical Inc. (United States), Nestlé Health Science (Switzerland), Mead Johnson & Company, LLC. (United States), Danone Nutricia (Netherlands), Abbott (United States), Dr. Schär (Italy), Promin Metabolics (United States), Ajinomoto Cambrooke, Inc. (United States), Juvela (United Kingdom) and Agios Pharmaceuticals Inc. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Phenylketonuria Drug market by Type, Application and Region.

On the basis of geography, the market of Phenylketonuria Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Rising healthcare expenditure

Market Drivers
  • Rising Number of Newborn Who Suffers from the Phenylketonuria
  • Increasing Healthcare Spending and Rising Healthcare Infrastructure in Developing Economies

Opportunities
  • Increasing Awareness about the Phenylketonuria Disease among the People Creates the Opportunities for Market

Restraints
  • Issues Related to Screening of Newborn are hindering the Market


Key Target Audience
Phenylketonuria Drug Producers, Phenylketonuria Drug Suppliers, Research and Development Institutes, Potential Investors, Hospitals, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Medications
  • Supplements 
  • Others
By Application
  • Household
  • Hospital
  • Others
By Symtomps
  • Classic
  • Mild
  • Benign

By Test
  • Diagnostic Test
  • Screening Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Newborn Who Suffers from the Phenylketonuria
      • 3.2.2. Increasing Healthcare Spending and Rising Healthcare Infrastructure in Developing Economies
    • 3.3. Market Trends
      • 3.3.1. Rising healthcare expenditure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Phenylketonuria Drug, by Type, Application, Symtomps, Test and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Phenylketonuria Drug (Value)
      • 5.2.1. Global Phenylketonuria Drug by: Type (Value)
        • 5.2.1.1. Medications
        • 5.2.1.2. Supplements 
        • 5.2.1.3. Others
      • 5.2.2. Global Phenylketonuria Drug by: Application (Value)
        • 5.2.2.1. Household
        • 5.2.2.2. Hospital
        • 5.2.2.3. Others
      • 5.2.3. Global Phenylketonuria Drug by: Symtomps (Value)
        • 5.2.3.1. Classic
        • 5.2.3.2. Mild
        • 5.2.3.3. Benign
      • 5.2.4. Global Phenylketonuria Drug by: Test (Value)
        • 5.2.4.1. Diagnostic Test
        • 5.2.4.2. Screening Test
      • 5.2.5. Global Phenylketonuria Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Phenylketonuria Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BioMarin Pharmaceutical Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Nestlé Health Science (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mead Johnson & Company, LLC. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danone Nutricia (Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dr. Schär (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Promin Metabolics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ajinomoto Cambrooke, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Juvela (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Agios Pharmaceuticals Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Phenylketonuria Drug Sale, by Type, Application, Symtomps, Test and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Phenylketonuria Drug (Value)
      • 7.2.1. Global Phenylketonuria Drug by: Type (Value)
        • 7.2.1.1. Medications
        • 7.2.1.2. Supplements 
        • 7.2.1.3. Others
      • 7.2.2. Global Phenylketonuria Drug by: Application (Value)
        • 7.2.2.1. Household
        • 7.2.2.2. Hospital
        • 7.2.2.3. Others
      • 7.2.3. Global Phenylketonuria Drug by: Symtomps (Value)
        • 7.2.3.1. Classic
        • 7.2.3.2. Mild
        • 7.2.3.3. Benign
      • 7.2.4. Global Phenylketonuria Drug by: Test (Value)
        • 7.2.4.1. Diagnostic Test
        • 7.2.4.2. Screening Test
      • 7.2.5. Global Phenylketonuria Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Phenylketonuria Drug: by Type(USD Million)
  • Table 2. Phenylketonuria Drug Medications , by Region USD Million (2015-2020)
  • Table 3. Phenylketonuria Drug Supplements  , by Region USD Million (2015-2020)
  • Table 4. Phenylketonuria Drug Others , by Region USD Million (2015-2020)
  • Table 5. Phenylketonuria Drug: by Application(USD Million)
  • Table 6. Phenylketonuria Drug Household , by Region USD Million (2015-2020)
  • Table 7. Phenylketonuria Drug Hospital , by Region USD Million (2015-2020)
  • Table 8. Phenylketonuria Drug Others , by Region USD Million (2015-2020)
  • Table 9. Phenylketonuria Drug: by Symtomps(USD Million)
  • Table 10. Phenylketonuria Drug Classic , by Region USD Million (2015-2020)
  • Table 11. Phenylketonuria Drug Mild , by Region USD Million (2015-2020)
  • Table 12. Phenylketonuria Drug Benign , by Region USD Million (2015-2020)
  • Table 13. Phenylketonuria Drug: by Test(USD Million)
  • Table 14. Phenylketonuria Drug Diagnostic Test , by Region USD Million (2015-2020)
  • Table 15. Phenylketonuria Drug Screening Test , by Region USD Million (2015-2020)
  • Table 16. South America Phenylketonuria Drug, by Country USD Million (2015-2020)
  • Table 17. South America Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 18. South America Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 19. South America Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 20. South America Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 21. Brazil Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 22. Brazil Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 23. Brazil Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 24. Brazil Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 25. Argentina Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 26. Argentina Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 27. Argentina Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 28. Argentina Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 29. Rest of South America Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 30. Rest of South America Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 31. Rest of South America Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 32. Rest of South America Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 33. Asia Pacific Phenylketonuria Drug, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 35. Asia Pacific Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 36. Asia Pacific Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 37. Asia Pacific Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 38. China Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 39. China Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 40. China Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 41. China Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 42. Japan Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 43. Japan Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 44. Japan Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 45. Japan Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 46. India Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 47. India Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 48. India Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 49. India Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 50. South Korea Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 51. South Korea Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 52. South Korea Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 53. South Korea Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 54. Taiwan Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 55. Taiwan Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 56. Taiwan Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 57. Taiwan Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 58. Australia Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 59. Australia Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 60. Australia Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 61. Australia Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 66. Europe Phenylketonuria Drug, by Country USD Million (2015-2020)
  • Table 67. Europe Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 68. Europe Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 69. Europe Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 70. Europe Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 71. Germany Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 72. Germany Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 73. Germany Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 74. Germany Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 75. France Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 76. France Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 77. France Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 78. France Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 79. Italy Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 80. Italy Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 81. Italy Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 82. Italy Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 83. United Kingdom Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 84. United Kingdom Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 85. United Kingdom Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 86. United Kingdom Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 87. Netherlands Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 88. Netherlands Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 89. Netherlands Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 90. Netherlands Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 91. Rest of Europe Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 92. Rest of Europe Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 93. Rest of Europe Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 94. Rest of Europe Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 95. MEA Phenylketonuria Drug, by Country USD Million (2015-2020)
  • Table 96. MEA Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 97. MEA Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 98. MEA Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 99. MEA Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 100. Middle East Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 101. Middle East Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 102. Middle East Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 103. Middle East Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 104. Africa Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 105. Africa Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 106. Africa Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 107. Africa Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 108. North America Phenylketonuria Drug, by Country USD Million (2015-2020)
  • Table 109. North America Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 110. North America Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 111. North America Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 112. North America Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 113. United States Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 114. United States Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 115. United States Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 116. United States Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 117. Canada Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 118. Canada Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 119. Canada Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 120. Canada Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 121. Mexico Phenylketonuria Drug, by Type USD Million (2015-2020)
  • Table 122. Mexico Phenylketonuria Drug, by Application USD Million (2015-2020)
  • Table 123. Mexico Phenylketonuria Drug, by Symtomps USD Million (2015-2020)
  • Table 124. Mexico Phenylketonuria Drug, by Test USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Phenylketonuria Drug: by Type(USD Million)
  • Table 136. Phenylketonuria Drug Medications , by Region USD Million (2021-2026)
  • Table 137. Phenylketonuria Drug Supplements  , by Region USD Million (2021-2026)
  • Table 138. Phenylketonuria Drug Others , by Region USD Million (2021-2026)
  • Table 139. Phenylketonuria Drug: by Application(USD Million)
  • Table 140. Phenylketonuria Drug Household , by Region USD Million (2021-2026)
  • Table 141. Phenylketonuria Drug Hospital , by Region USD Million (2021-2026)
  • Table 142. Phenylketonuria Drug Others , by Region USD Million (2021-2026)
  • Table 143. Phenylketonuria Drug: by Symtomps(USD Million)
  • Table 144. Phenylketonuria Drug Classic , by Region USD Million (2021-2026)
  • Table 145. Phenylketonuria Drug Mild , by Region USD Million (2021-2026)
  • Table 146. Phenylketonuria Drug Benign , by Region USD Million (2021-2026)
  • Table 147. Phenylketonuria Drug: by Test(USD Million)
  • Table 148. Phenylketonuria Drug Diagnostic Test , by Region USD Million (2021-2026)
  • Table 149. Phenylketonuria Drug Screening Test , by Region USD Million (2021-2026)
  • Table 150. South America Phenylketonuria Drug, by Country USD Million (2021-2026)
  • Table 151. South America Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 152. South America Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 153. South America Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 154. South America Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 155. Brazil Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 156. Brazil Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 157. Brazil Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 158. Brazil Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 159. Argentina Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 160. Argentina Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 161. Argentina Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 162. Argentina Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 163. Rest of South America Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 164. Rest of South America Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 165. Rest of South America Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 166. Rest of South America Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 167. Asia Pacific Phenylketonuria Drug, by Country USD Million (2021-2026)
  • Table 168. Asia Pacific Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 169. Asia Pacific Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 170. Asia Pacific Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 171. Asia Pacific Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 172. China Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 173. China Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 174. China Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 175. China Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 176. Japan Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 177. Japan Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 178. Japan Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 179. Japan Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 180. India Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 181. India Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 182. India Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 183. India Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 184. South Korea Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 185. South Korea Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 186. South Korea Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 187. South Korea Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 188. Taiwan Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 189. Taiwan Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 190. Taiwan Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 191. Taiwan Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 192. Australia Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 193. Australia Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 194. Australia Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 195. Australia Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 200. Europe Phenylketonuria Drug, by Country USD Million (2021-2026)
  • Table 201. Europe Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 202. Europe Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 203. Europe Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 204. Europe Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 205. Germany Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 206. Germany Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 207. Germany Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 208. Germany Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 209. France Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 210. France Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 211. France Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 212. France Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 213. Italy Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 214. Italy Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 215. Italy Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 216. Italy Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 217. United Kingdom Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 218. United Kingdom Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 219. United Kingdom Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 220. United Kingdom Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 221. Netherlands Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 222. Netherlands Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 223. Netherlands Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 224. Netherlands Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 225. Rest of Europe Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 226. Rest of Europe Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 227. Rest of Europe Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 228. Rest of Europe Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 229. MEA Phenylketonuria Drug, by Country USD Million (2021-2026)
  • Table 230. MEA Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 231. MEA Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 232. MEA Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 233. MEA Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 234. Middle East Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 235. Middle East Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 236. Middle East Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 237. Middle East Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 238. Africa Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 239. Africa Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 240. Africa Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 241. Africa Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 242. North America Phenylketonuria Drug, by Country USD Million (2021-2026)
  • Table 243. North America Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 244. North America Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 245. North America Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 246. North America Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 247. United States Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 248. United States Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 249. United States Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 250. United States Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 251. Canada Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 252. Canada Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 253. Canada Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 254. Canada Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 255. Mexico Phenylketonuria Drug, by Type USD Million (2021-2026)
  • Table 256. Mexico Phenylketonuria Drug, by Application USD Million (2021-2026)
  • Table 257. Mexico Phenylketonuria Drug, by Symtomps USD Million (2021-2026)
  • Table 258. Mexico Phenylketonuria Drug, by Test USD Million (2021-2026)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Phenylketonuria Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Phenylketonuria Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Phenylketonuria Drug: by Symtomps USD Million (2015-2020)
  • Figure 7. Global Phenylketonuria Drug: by Test USD Million (2015-2020)
  • Figure 8. South America Phenylketonuria Drug Share (%), by Country
  • Figure 9. Asia Pacific Phenylketonuria Drug Share (%), by Country
  • Figure 10. Europe Phenylketonuria Drug Share (%), by Country
  • Figure 11. MEA Phenylketonuria Drug Share (%), by Country
  • Figure 12. North America Phenylketonuria Drug Share (%), by Country
  • Figure 13. Global Phenylketonuria Drug share by Players 2020 (%)
  • Figure 14. Global Phenylketonuria Drug share by Players (Top 3) 2020(%)
  • Figure 15. Global Phenylketonuria Drug share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. BioMarin Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. BioMarin Pharmaceutical Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Nestlé Health Science (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Nestlé Health Science (Switzerland) Revenue: by Geography 2020
  • Figure 21. Mead Johnson & Company, LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Mead Johnson & Company, LLC. (United States) Revenue: by Geography 2020
  • Figure 23. Danone Nutricia (Netherlands) Revenue, Net Income and Gross profit
  • Figure 24. Danone Nutricia (Netherlands) Revenue: by Geography 2020
  • Figure 25. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott (United States) Revenue: by Geography 2020
  • Figure 27. Dr. Schär (Italy) Revenue, Net Income and Gross profit
  • Figure 28. Dr. Schär (Italy) Revenue: by Geography 2020
  • Figure 29. Promin Metabolics (United States) Revenue, Net Income and Gross profit
  • Figure 30. Promin Metabolics (United States) Revenue: by Geography 2020
  • Figure 31. Ajinomoto Cambrooke, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Ajinomoto Cambrooke, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Juvela (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Juvela (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Agios Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Agios Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Global Phenylketonuria Drug: by Type USD Million (2021-2026)
  • Figure 38. Global Phenylketonuria Drug: by Application USD Million (2021-2026)
  • Figure 39. Global Phenylketonuria Drug: by Symtomps USD Million (2021-2026)
  • Figure 40. Global Phenylketonuria Drug: by Test USD Million (2021-2026)
  • Figure 41. South America Phenylketonuria Drug Share (%), by Country
  • Figure 42. Asia Pacific Phenylketonuria Drug Share (%), by Country
  • Figure 43. Europe Phenylketonuria Drug Share (%), by Country
  • Figure 44. MEA Phenylketonuria Drug Share (%), by Country
  • Figure 45. North America Phenylketonuria Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • BioMarin Pharmaceutical Inc. (United States)
  • Nestlé Health Science (Switzerland)
  • Mead Johnson & Company, LLC. (United States)
  • Danone Nutricia (Netherlands)
  • Abbott (United States)
  • Dr. Schär (Italy)
  • Promin Metabolics (United States)
  • Ajinomoto Cambrooke, Inc. (United States)
  • Juvela (United Kingdom)
  • Agios Pharmaceuticals Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 240 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Phenylketonuria Drug Quantitative research analysis
Global Phenylketonuria Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Phenylketonuria Drug Report?

Have a Query? Click Here

Other Related Reports

Pneumonia Vaccine Comprehensive Study by Type (Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23)), Patient Type (Pediatric Patients, Adult Patients), Distribution C...
$ 3350
Scopolamine Comprehensive Study by Type (Scopolamine Butylbromide, Scopolamine Hydrobromide, Scopolamine Base), Application (Oral, Injection, Patches), Form (Tablet, Syrup), Distribution Channel (Hos...
$ 3650
Pharmaceutical Lab Equipment Comprehensive Study by Type (General instrument, Analytical instrument, Specialty instrument, Others), Application (Research Institutions, Academic laboratory, Pharmaceut...
$ 3450
Interferon Comprehensive Study by Application (Oncology, Autoimmune Disorders, Diabetes, Inflammatory and Infectious Diseases, Neurological Diseases, Cardiovascular Diseases, Others), Drug Type (Inte...
$ 3750
Phytosterols Comprehensive Study by Type (Beta-Sitosterol, Campesterol, Stigmasterol, Others), Application (Dairy Products, Beverages, Sauces and Condiments, Bakery and Confectionery, Pharmaceutical,...
$ 3500
Steroids Comprehensive Study by Type (Corticosteroids, Anabolic), Application (Health care products, Daily diet, Hospital, Clinic, Others), Distribution Channel (Online Retail, Offline Retail), For...
$ 3500